Chester County News and Community Website
KING OF PRUSSIA, PA — Alector, Inc. announced that its experimental therapy latozinemab failed to meet primary efficacy and safety endpoints in a Phase 3 clinical trial evaluating the drug …
Alector’s Phase 3 Trial of Latozinemab Fails to Meet Efficacy Endpoints in FTD-GRN Study Read More
WILMINGTON, DE — AstraZeneca and Daiichi Sankyo reported that their antibody-drug conjugate ENHERTU® (fam-trastuzumab deruxtecan-nxki), when used before surgery and followed by standard therapy, achieved a pathologic complete response in …
ENHERTU Combination Shows Promising Results in Early Breast Cancer Trial Read More WILMINGTON, DE — AstraZeneca announced that its IMFINZI (durvalumab) regimen significantly reduced the risk of disease recurrence or death by 32 percent in patients with high-risk, non-muscle-invasive bladder cancer (NMIBC) …
IMFINZI Combination Cuts Disease Recurrence Risk by 32% in Early Bladder Cancer Trial Read More WILMINGTON, DE — AstraZeneca announced new data from its Phase III MATTERHORN trial showing that its immunotherapy IMFINZI (durvalumab), when used in combination with standard FLOT chemotherapy, reduced the risk …
AstraZeneca Reports IMFINZI-Based Regimen Cuts Death Risk by 22% in Early Gastric Cancer Read More
NEWTOWN, PA — Micro Interventional Devices (MID) announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Investigational Device Exemption (IDE), allowing the company to begin …
Micro Interventional Devices Secures FDA Approval to Launch Pivotal U.S. Trial for Tricuspid Valve Repair Technology Read More
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has begun dosing participants in a Phase 2 clinical trial evaluating ratutrelvir, a ritonavir-free antiviral therapy for newly diagnosed COVID-19 patients. The …
Traws Pharma Begins Phase 2 Trial of Ritonavir-Free COVID-19 Treatment Ratutrelvir Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has received the second year of funding under its U.S. Food and Drug Administration (FDA) Office of Orphan Products Development …
Palvella Therapeutics Receives Second Year of FDA Grant Funding for Phase 3 SELVA Trial Read More WILMINGTON, DE — Positive results from the Phase III Bax24 trial show that baxdrostat achieved statistically significant and clinically meaningful reductions in 24-hour systolic blood pressure (SBP) among patients with …
Baxdrostat Achieves Breakthrough Blood Pressure Reductions in Phase III Bax24 Trial Read More WILMINGTON, DE — AstraZeneca and Daiichi Sankyo announced that their jointly developed therapy, DATROWAY® (datopotamab deruxtecan-dlnk), achieved positive top-line results in the Phase III TROPION-Breast02 trial, marking a major advancement …
AstraZeneca and Daiichi Sankyo Report Breakthrough Results for DATROWAY® in Advanced Breast Cancer Trial Read More
SPRING HOUSE, PA — Johnson & Johnson (NYSE: JNJ) released new 48-week results from its Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) as a subcutaneous induction and maintenance therapy for …
Johnson & Johnson’s TREMFYA® Shows Sustained One-Year Efficacy in Ulcerative Colitis Read More